Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study
卡瑞利珠单抗联合卡铂和培美曲塞作为晚期非鳞状非小细胞肺癌一线治疗：CameL随机3期研究的5年结果
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2024-009240
Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, XiaoRong; Jin, Faguang; Gao, Hongjun; An, Guangyu; Ding, Cuimin; Jiang, Xiaodong; Xiong, Jianping; Zhou, Xiangdong; Hu, Sheng; Lu, Ping; Liu, Anwen; Guo, Shuliang; Huang, Jianjin; Zhu, Chengchu; Zhao, Jian; Gao, Beili; Chen, Yinglan; Hu, Chengping; Zhang, Jian; Zhang, Hongmei; Zhao, Hui; Wang, Zhigao; Ma, Xinjing; Shi, Wei
